

0040-4039(93)E0298-X

A Stereoselective Synthesis of 8(R) and 8(S), 11(R), 12(S)-Trihydroxyeicosa-5(Z), 9(E), 14(Z)-Trienoic Acid from 2-Deoxy-D-Ribose


Yadav J S* and Prahlad Vadapalli

Indian Institute of Chemical Technology, Hyderabad 500007, India

Abstract: A stereoselective synthesis of stereoisomers of the title compound from 2-deoxy-D-Ribose using reductive elimination protocol as the key step is described.


Hepoxilins^{2,3} are biologically potent epoxy alcohols derived from 12(S) HPETE via 12-lipoxygenation pathways and play⁴ crucial role in haemostasis and several respiratory disorders. Recent findings have also shown that they have insulin secretagogue activity⁵ and have possible role as second messengers for presynaptic inhibitors of Aplysia sensory cells⁶ which brought these compounds to the fore. Scarce availability of hepoxilins obscured the exact mode of their action in pharmacological profile. Trioxilin A₃, formed from Hepoxilin A₃ via the same 12-lipoxygenase pathway involving epoxide hydratase enzyme, has been identified⁷ as a mixture of 8R/S, 11R, 12S-trihydroxyeicosa-5Z, 9E, 14Z-trienoic acid. To extend the scope of further exploration of the physiological importance of this novel class of eicosanoids and also to study the bioefficacy of hepoxilins and trioxilin A₃ in particular, we herein report a practical and stereoselective total synthesis of both 8R and 8S isomers of trioxilin A₃, from the chiral precursor 2-deoxy-D-ribose in which the C-3 and C-4 chiral centres are correlated to the 12S and 11R carbon centres of the target molecule.

The following retrosynthetic analysis (scheme 1) reveals the strategy.



The crucial E-olefinic system present at C-9 of 1 can be envisioned from the stereocontrolled Wittig olefination⁸ of chiral carbinal 2 with the ylide of 3. IICT Communication No.3301.

Further, the chiral retron **2** can be synthesized in high yields by the methodology recently developed by us¹ involving reductive elimination of the dichloromethylene compound **4**. The chiral retron **2**, was prepared from 2-deoxy-D-ribose in 7 steps as delineated in scheme 2.




Reagents and reaction Conditions:

(i) 2-Methoxypropene, PPTS, EtOAc, rt, 3h (ii) Br₂-CaCO₃, Acetonitrile:H₂O (5:1), rt, 24h (iii) PPh₃, CCl₄, THF reflux (iv) Li sand, THF, reflux, 3h (v) n-BuLi, pentyl bromide, THF:HMPA (10:1), -78° to rt (vi) Pd-CaCO₃, H₂, EtOH, 3h (vii) (COCl)₂, DMSO, TEA, DCM, -78°C.

Protection of the hydroxyl groups of 2-deoxy-D-ribose⁹ with 2-methoxy propene under PPTS conditions led to rearranged product **7**. Oxidation of lactal **7** to lactone **8** was achieved in 85% yields under Br₂-CaCO₃ conditions. Chapleur's¹⁰ method of dichloromethylenation of **8** led to **4** in good yields. The crucial synthon **9** was obtained from **4** in 85-90% yields by following our reductive elimination process.^{1,11} Alkylation of the lithium alkylide of **9** with amyl bromide followed by hydrogenation under Lindlar's conditions have the Z-olefinic alcohol **11** in overall 80% yield. Swern oxidation of **11** afforded the intermediate **2** in 80% yield.

The retron **3** was prepared efficiently by a new route from the commercially available epichlorohydrin **5** and 5-hexynoic acid **6**, employing Yamaguchi's¹² method of oxirane opening with alkynyl boranes as shown in scheme 3.




Reagents and reaction conditions:

(i) SOCl₂, Pyridine, rt, 10h (ii) NaNH₂, liq. NH₃, -78°, THF (iii) Jones' reagent, acetone, 0° (iv) n-BuLi, BF₃ (OEt)₂, epichlorohydrin, -78°, THF (v) CH₂N₂, ether (vi) Jones' reagent, acetone, 0°C.

Hexynoic acid **6** was prepared in substantial yields by base induced double elimination of tetrahydropyranylchloride **13** leading to acetylenic alcohol **14** followed by Jones' oxidation. Treatment of **6** with two equivalents of *n*-BuLi at -78°C followed by the addition of **5** led uneventfully to **15a** in 65% yields. Chloroketone **3** was prepared from **15a** via a sequence of reaction involving conversion of acid to methyl ester **15b**, hydrogenation over Lindlar's catalyst and then Jones' oxidation in overall 70% yield.¹³

The final conversion to the target molecule **1** through the stereocontrolled Wittig olefination⁸ of **2** with the stable ylide **16** prepared from retron **3** is depicted in scheme 4.



Reagents and reaction conditions:

(i) Benzene, rt, 10h (ii) NaBH_4 , methanol, 0° , 10min (iii) 6N HCl, THF, rt, 6h (iv) LiOH, MeOH- H_2O (2:1), 28°C , 10h.

Chloroketone **3** was converted to its corresponding triphenyl phosphonium salt on treatment with one equivalent of Ph_3P in CHCl_3 followed by base treatment which gave ylide **16**. Aldehyde **2** was added to ylide in dry benzene and stirred at room temperature to result in the *E*-olefinic product **17** in 80% yield, well confirmed by NMR spectrum.¹⁴ Reduction of **17** with NaBH_4 in methanol at 0° gave diastereomeric mixture **18** (80% yield) in the ratio of 3:2 corresponding to **18a** and **18b** respectively, separable by flash column chromatography. Acetonide deprotection of **18a** and **18b** gave the triol esters **19a** and **19b** respectively, which were concurrent with the spectral data and specific rotations of the reported values,¹⁵ **19a** $[\alpha]_{\text{D}} -8.122^{\circ}(\text{C } 0.5 \text{ CCl}_4)$ (lit $-8.0^{\circ}; \text{C } 0.65 \text{ CCl}_4$), **19b** $[\alpha]_{\text{D}} +3.066^{\circ}(\text{C } 1.2 \text{ CCl}_4)$ (lit $+2.8^{\circ}; \text{C } 0.58 \text{ CCl}_4$). Further saponification of **19a** and **19b** resulted in the title compounds **1a** and **1b**.

Thus, the synthesis of title compounds have been demonstrated by a concise and convenient route involving the reductive elimination reaction developed by us as a key step.

References and Notes

1. Yadav, J.S.; Prahlad, V. and Chander, M.C. *J.Chem.Soc.,Chem.Commu.* **1993**, 317-318.
 2. (a) Walker, I.C.; Jones, R.L. and Wilson, N.H. *Prostaglandins* **1979**, *18*, 173.
(b) Pace-Asciak, C.R.; Mizumo, K. and Yamamoto, S. *Biochim Biophys Acta*, **1982**, *712*, 142.
 3. Corey, E.J.; Kang, J.; Laguzza, B.C. and Jones, R.L. *Tetrahedron Lett.* **1983**, *24*, 4913.
 4. Samuelsson, B.; Dahlem, S.E.; Lindgren, J.A.; Rouzer, C.A.; Serham, C.N. *Science* **1987**, *237*, 1171.
 5. Pace-Asciak, C.R.; Martin, J.M. and Corey, E.J.; *Prog Lipid Res.* **1986**, *25*, 625.
 6. Piomelli, D.; Feinmark, S.J. and Schwartz, J.H. Society for Neuroscience, 17th Annual Meeting, New Orleans, Louisiana, November 16-21, **1987**. Abstract No.169.11, p 598.
 7. Pace-Asciak, C.R.; Laneville, O.; Su, W-g.; Corey, E.J.; Gurevich, N.; Wu, P. and Carlen, P.L. *Proc. Natl. Acad. Sci. USA*, **1990**, *87*, 3097-3041.
 8. Corey, E.J. and Su, W-g. *Tetrahedron Lett.* **1984**, *25*, 5119-5122.
 9. Corey, E.J.; Marfat, A.; Goto, G. and Brias, F. *J.Am.Chem.Soc.* **1980**, *102*, 7984-7985.
 10. Lakhrissi, M. and Chapleur, Y. *Syn.Lett.* **1991**, 583.
 11. Spectral data for **9**: 200 MHz ^1H NMR (CDCl_3): δ 4.40-4.20 (m,2H), 3.85-3.65 (dd,2H), $J=6.13,4.08$ Hz, 2.55-2.45 (m,2H), 2.05 (t,1H, $J=2.0$ Hz), 1.45 (s,3H), 1.35 (s,3H); $[\alpha]_{\text{D}} +16.4^\circ$ (C 0.5, CHCl_3).
 12. Yamaguchi, M. and Ichiro, H. *Tetrahedron Lett.* **1983**, *24*, 391-394.
 13. Spectral data for **3**: 200 MHz ^1H NMR (CDCl_3): δ 5.65-5.50 (m,2H), 4.1 (s,2H), 3.65 (s,3H), 3.35 (d,2H, $J=6.4$ Hz), 2.29 (t,2H, $J=7.5$ Hz), 2.05 (q,2H, $J=6.3,9.6$ Hz), 1.75-1.60 (m,2H).
 14. Spectral data for **17**: 200 MHz ^1H NMR (CDCl_3): δ 6.65 (dd,1H, $J=16.3,5.8$ Hz), 6.4 (d,1H,16.3 Hz), 5.6-5.4 (m,4H), 4.7 (dd,1H, $J=6.3,5.4$ Hz), 4.3-4.2 (dt,1H, $J=6.3,13.0$ Hz), 3.7 (s,3H), 3.3 (d,2H, $J=6.3$ Hz), 2.4-2.0 (m,8H), 1.8-1.4 (m,8H), 1.38 (s,3H), 1.37 (s,3H), 0.9 (t,3H, $J=6.3$ Hz); $[\alpha]_{\text{D}} -3.9^\circ$ (C 0.9, CHCl_3).
 15. Lumin, S.; Falck, J.R.; Capdevilla, J. and Karara, A. *Tetrahedron Lett.* **1992**, *33*, 2091.
- * All the new compounds gave expected spectral data including HRMS.

(Received in UK 14 October 1993; revised 24 November 1993; accepted 26 November 1993)